about
Open science versus commercialization: a modern research conflict?When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility CrisisChanging R&D; models in research-based pharmaceutical companiesA systematic review and critical assessment of incentive strategies for discovery and development of novel antibioticsTranslational research and the evolving landscape for biomedical innovationDesigning the next generation of medicines for malaria control and eradicationAccelerating Translational Research through Open Science: The Neuro ExperimentStimulated Raman scattering microscopy: an emerging tool for drug discoveryThe promises of quantitative systems pharmacology modelling for drug developmentEnhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case studyIn vitro and in vivo activities of ruthenium(II) phosphine/diimine/picolinate complexes (SCAR) against Mycobacterium tuberculosisPatented drug extension strategies on healthcare spending: a cost-evaluation analysisTracking 20 years of compound-to-target output from literature and patentsOpen access target validation is a more efficient way to accelerate drug discoveryDrug Pricing Evolution in Hepatitis CUnderstanding Fear of Opportunism in Global Prize-Based Science Contests: Evidence for Gender and Age DifferencesOpen Source Bayesian Models. 1. Application to ADME/Tox and Drug Discovery DatasetsCollaboration for rare disease drug discovery researchHistorical perspective of traditional indigenous medical practices: the current renaissance and conservation of herbal resourcesOpen access high throughput drug discovery in the public domain: a Mount Everest in the making.Stock market returns and clinical trial results of investigational compounds: an event study analysis of large biopharmaceutical companiesComputational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanismsDrug design for ever, from hype to hopeIs Open Science the Future of Drug Development?Preparedness of the CTSA's structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS)Tinnitus: network pathophysiology-network pharmacology.Evaluation of research in biomedical ontologiesOpen Access Could Transform Drug Discovery: A Case Study of JQ1.Decline in new drug launches: myth or reality? Retrospective observational study using 30 years of data from the UKThe concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative.Big Data in Pharmaceutical R&D: Creating a Sustainable R&D Engine.Building a drug development database: challenges in reliable data availability.Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases.Integrating Clinical Phenotype and Gene Expression Data to Prioritize Novel Drug UsesTrial watch: global migration of clinical trialsAging biology and novel targets for drug discovery.The battle of Alzheimer's Disease - the beginning of the future Unleashing the potential of academic discoveries.ZeGlobalTox: An Innovative Approach to Address Organ Drug Toxicity Using Zebrafish.Targeting the undruggable proteome: the small molecules of my dreams.Discovery of N-(2-aminoethyl)-N-benzyloxyphenyl benzamides: New potent Trypanosoma brucei inhibitors.
P2860
Q22256036-ED523CE3-678B-4E43-95B4-2E2FB3346D41Q24288687-A52F6AEB-EE1D-426A-B1AF-A462724C5DDBQ26749511-709A00A0-5DCE-4BDD-98E9-B795DAB0F577Q26783545-0915E915-BB1D-42E5-BE86-0C621665F6C4Q26851873-DAD18B96-94A3-49FE-B897-8B34BF495AB7Q26859195-92562ECB-235A-477B-8AF3-D1E616C1B165Q27976622-A7BF928E-9921-43C2-ACB9-15D842B8FD42Q28067096-02BDDB0C-3123-4F52-B29C-65655783B913Q28077650-9D60DE0F-1FF1-45EB-A210-94CB3DA77483Q28084489-916A62D9-6567-4D3F-88B0-C16222068218Q28533382-CADBDC84-95DB-4F0B-B205-62ED7FE369B2Q28533630-A498F938-D79F-4E23-894A-A071C73074BAQ28534695-B31C4EB5-8AB6-4B76-ABBB-B65306EADBDCQ28547855-2DD9EFA4-D1DA-4797-B068-E74E0C26C35FQ28550311-1E1C5FEA-B3D6-4FBA-9058-D0E601A1E274Q28645855-CC8FBD4E-EB3F-48DC-9EAF-EF282FB34FB3Q28647980-8A244C76-D292-4757-8DA6-B60FFC984259Q28650560-21CF079F-B604-4F8D-AE7F-A2E41EB5AC24Q28657343-B5A5AF01-8892-4E28-AE97-D5BEE9DCF69EQ28677005-507E1FD2-34B9-4DAF-9F2A-2027F613B784Q28686746-C37EE34D-82C1-4CCE-9D02-634082CBECDCQ28730803-5922BA51-43FA-46D4-B4BF-58B09AB9D303Q28732341-829D5680-0A6C-4274-960A-9D2490343A42Q29237434-58951E82-2E29-4837-B7A5-46008A0684F0Q30224653-F4EDD43B-320C-48C9-911D-3B762EAD34ADQ30412371-2993DFEA-D690-4F16-9399-355F61231A59Q30421082-808D8539-217B-4351-BA30-3D2340BECF19Q30488815-B5C7D009-22B9-4CF4-955C-3531488DF88AQ30591600-829E64EC-51E2-4CED-B5D9-6989DC905F41Q30854543-DDB190A6-D419-4B3E-BA14-4D177E7833AFQ30933660-DCB940F4-69C3-4597-9495-1FDEAC8EF37DQ31119778-09FD875D-BC95-4DF0-A8E9-7575BD3084D6Q31138564-4807F07C-0C5F-4726-BC15-84704BBEE8FEQ31143112-49F6DE21-F03F-4EDE-8E4C-144A9D8F3C3CQ33551360-71B27BF9-7070-4B47-8AD7-98A060AE156BQ33558234-10F879A9-EB6E-4D19-BF74-FC7A2D0B997AQ33620099-E637265C-D0DD-44BA-997E-676CA0F0A73DQ33624909-1FA76A0E-E2DF-40C2-91B9-E6B4F7D0151FQ33627085-0A8DC2AB-077C-472D-8BBD-184A772401ADQ33643131-E9DDFEC8-5E79-4AE7-9C16-1A0C19342E26
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Lessons from 60 years of pharmaceutical innovation.
@en
Lessons from 60 years of pharmaceutical innovation.
@nl
type
label
Lessons from 60 years of pharmaceutical innovation.
@en
Lessons from 60 years of pharmaceutical innovation.
@nl
altLabel
Lessons from 60 years of pharmaceutical innovation
@en
prefLabel
Lessons from 60 years of pharmaceutical innovation.
@en
Lessons from 60 years of pharmaceutical innovation.
@nl
P356
P1476
Lessons from 60 years of pharmaceutical innovation.
@en
P2888
P304
P356
10.1038/NRD2961
P577
2009-12-01T00:00:00Z
P5875
P6179
1014842622